Home / Resource Library / Acalabrutinib in Waldenstrom macroglobulinemia yields durable responses with 5 years of follow-up

Acalabrutinib in Waldenstrom macroglobulinemia yields durable responses with 5 years of follow-up

Results of a study investigating acalabrutinib for treatment of Waldenstom macroglobulinemia.